- References (3)
- Inventor Info
|Antigen/Gene or Protein Targets||BCAR3, BCAR4, AKT1|
|Disease Keywords||Mammary adenocarcinoma, estrogen-dependent|
Endocrine therapy of breast cancer has been applied widely and proven to be effective. However, in many instances endocrine treatments ultimately fail due to the development of an estrogen-independent therapy resistant phenotype. To elucidate the molecular mechanism underlying this endocrine therapy failure, the laboratory of Lambert Dorssers applied different genetic screens to identify the main genes conferring estrogen independence.
Out of 15 candidate BCAR genes, several including BCAR3, BCAR4 and AKT1 were shown to directly underlie estrogen independence to MCF7A breast cancer cells. These genes were transfected into the MCF7A breast cancer cell line resulting in a panel of 4 cell lines (Cat No 154636-154638, 154643).
These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
|Production Details||Full length cDNA of the relevant gene was introduced in the estrogen-dependant MCF7A cell line by transfection with lipofectamine|
|Research Area||Cancer, Drug Discovery & Development|
|Recommended Growing Conditions||RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS)|
|Notes||The cell lines are also resistant to Geneticin which may be included in the culture to maintain the expression plasmid|
There are 3 reference entries for this reagent.View All References
No inventors are currently linked to this reagent.
Add an inventor
Add an inventor